361 related articles for article (PubMed ID: 16887103)
1. Cytochrome P450 reductase dependent inhibition of cytochrome P450 2B1 activity: Implications for gene directed enzyme prodrug therapy.
Lengler J; Omann M; Düvier D; Holzmüller H; Gregor W; Salmons B; Günzburg WH; Renner M
Biochem Pharmacol; 2006 Sep; 72(7):893-901. PubMed ID: 16887103
[TBL] [Abstract][Full Text] [Related]
2. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene.
Chen L; Waxman DJ; Chen D; Kufe DW
Cancer Res; 1996 Mar; 56(6):1331-40. PubMed ID: 8640822
[TBL] [Abstract][Full Text] [Related]
3. Potentiation of cytochrome P450/cyclophosphamide-based cancer gene therapy by coexpression of the P450 reductase gene.
Chen L; Yu LJ; Waxman DJ
Cancer Res; 1997 Nov; 57(21):4830-7. PubMed ID: 9354446
[TBL] [Abstract][Full Text] [Related]
4. Necrotic, rather than apoptotic, cell death caused by cytochrome P450-activated ifosfamide.
Karle P; Renner M; Salmons B; Günzburg WH
Cancer Gene Ther; 2001 Mar; 8(3):220-30. PubMed ID: 11332993
[TBL] [Abstract][Full Text] [Related]
5. Effects of hypoxia and limited diffusion in tumor cell microenvironment on bystander effect of P450 prodrug therapy.
Günther M; Waxman DJ; Wagner E; Ogris M
Cancer Gene Ther; 2006 Aug; 13(8):771-9. PubMed ID: 16543915
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy.
Chen L; Waxman DJ
Cancer Res; 1995 Feb; 55(3):581-9. PubMed ID: 7834628
[TBL] [Abstract][Full Text] [Related]
7. Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer.
Roy P; Waxman DJ
Toxicol In Vitro; 2006 Mar; 20(2):176-86. PubMed ID: 16293390
[TBL] [Abstract][Full Text] [Related]
8. Diffusible cytotoxic metabolites contribute to the in vitro bystander effect associated with the cyclophosphamide/cytochrome P450 2B1 cancer gene therapy paradigm.
Wei MX; Tamiya T; Rhee RJ; Breakefield XO; Chiocca EA
Clin Cancer Res; 1995 Oct; 1(10):1171-7. PubMed ID: 9815909
[TBL] [Abstract][Full Text] [Related]
9. Enantioselective metabolism and cytotoxicity of R-ifosfamide and S-ifosfamide by tumor cell-expressed cytochromes P450.
Chen CS; Jounaidi Y; Waxman DJ
Drug Metab Dispos; 2005 Sep; 33(9):1261-7. PubMed ID: 15919850
[TBL] [Abstract][Full Text] [Related]
10. Targeted chemotherapy by intratumour injection of encapsulated cells engineered to produce CYP2B1, an ifosfamide activating cytochrome P450.
Löhr M; Müller P; Karle P; Stange J; Mitzner S; Jesnowski R; Nizze H; Nebe B; Liebe S; Salmons B; Günzburg WH
Gene Ther; 1998 Aug; 5(8):1070-8. PubMed ID: 10326030
[TBL] [Abstract][Full Text] [Related]
11. Peritoneal cancer treatment with CYP2B1 transfected, microencapsulated cells and ifosfamide.
Samel S; Keese M; Lux A; Jesnowski R; Prosst R; Saller R; Hafner M; Sturm J; Post S; Löhr M
Cancer Gene Ther; 2006 Jan; 13(1):65-73. PubMed ID: 16096652
[TBL] [Abstract][Full Text] [Related]
12. Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy.
Jounaidi Y; Hecht JE; Waxman DJ
Cancer Res; 1998 Oct; 58(19):4391-401. PubMed ID: 9766669
[TBL] [Abstract][Full Text] [Related]
13. Impact of liver P450 reductase suppression on cyclophosphamide activation, pharmacokinetics and antitumoral activity in a cytochrome P450-based cancer gene therapy model.
Huang Z; Raychowdhury MK; Waxman DJ
Cancer Gene Ther; 2000 Jul; 7(7):1034-42. PubMed ID: 10917206
[TBL] [Abstract][Full Text] [Related]
14. Antitumour prodrug development using cytochrome P450 (CYP) mediated activation.
Patterson LH; McKeown SR; Robson T; Gallagher R; Raleigh SM; Orr S
Anticancer Drug Des; 1999 Dec; 14(6):473-86. PubMed ID: 10834269
[TBL] [Abstract][Full Text] [Related]
15. Sustained P450 expression and prodrug activation in bolus cyclophosphamide-treated cultured tumor cells. Impact of prodrug schedule on P450 gene-directed enzyme prodrug therapy.
Schwartz PS; Chen CS; Waxman DJ
Cancer Gene Ther; 2003 Aug; 10(8):571-82. PubMed ID: 12872138
[TBL] [Abstract][Full Text] [Related]
16. Frequent, moderate-dose cyclophosphamide administration improves the efficacy of cytochrome P-450/cytochrome P-450 reductase-based cancer gene therapy.
Jounaidi Y; Waxman DJ
Cancer Res; 2001 Jun; 61(11):4437-44. PubMed ID: 11389073
[TBL] [Abstract][Full Text] [Related]
17. Combined chemotherapy of murine mammary tumors by local activation of the prodrugs ifosfamide and 5-fluorocytosine.
Kammertoens T; Gelbmann W; Karle P; Alton K; Saller R; Salmons B; Günzburg WH; Uckert W
Cancer Gene Ther; 2000 Apr; 7(4):629-36. PubMed ID: 10811482
[TBL] [Abstract][Full Text] [Related]
18. Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics.
Chen CS; Lin JT; Goss KA; He YA; Halpert JR; Waxman DJ
Mol Pharmacol; 2004 May; 65(5):1278-85. PubMed ID: 15102956
[TBL] [Abstract][Full Text] [Related]
19. Enhanced bystander cytotoxicity of P450 gene-directed enzyme prodrug therapy by expression of the antiapoptotic factor p35.
Schwartz PS; Chen CS; Waxman DJ
Cancer Res; 2002 Dec; 62(23):6928-37. PubMed ID: 12460909
[TBL] [Abstract][Full Text] [Related]
20. Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene.
Pawlik TM; Nakamura H; Mullen JT; Kasuya H; Yoon SS; Chandrasekhar S; Chiocca EA; Tanabe KK
Cancer; 2002 Sep; 95(5):1171-81. PubMed ID: 12209705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]